ABSTRACT
BACKGROUND: Controversy exists regarding proportional contributions of mammographic screening versus systemic therapy to declining disease-specific mortality of female invasive breast cancer (IBC) in the United States. Understanding relative contributions may help address allocation of medical resources. METHODS: A 31-year (1987-2017) review of Rhode Island (RI) Cancer Registry data of female IBC was carried out in a state with high rates of mammographic screening. RESULTS: Over 31 years in RI, statistically significant improvements occurred at initial diagnosis of IBC: mean and median maximum cancer diameters decreased by 21% and 30% respectively. Despite 1997 introduction of more accurate sentinel lymph node biopsy, the proportion of patients with axillary lymph node metastases (LNM) decreased by 27%. Extent of LNM also decreased as patients with over three node metastases decreased 67%. By 2017, 53% of all patients with LNM had only one. Poorly differentiated cancers decreased 50%. Disease-specific mortality decreased 57%. DISCUSSION: Improvements in initial presentation of IBC are consistent with most having progressive growth, from cellular origin to palpable mass, the currently accepted biological model. Breast cancers identified earlier at initial diagnosis through screening mammography are characterized by smaller size, fewer axillary LNMs, better grade differentiation, and decreased mortality. Statistical analysis from these improved diagnostic parameters indicate that the majority of mortality decline from invasive breast cancer in RI can be attributed to earlier detection. Thus, mammography predominates in preventing mortality.
Subject(s)
Breast Neoplasms , Mammography , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/epidemiology , Early Detection of Cancer , Female , Humans , Mass Screening , Rhode Island/epidemiologyABSTRACT
Breast cancer survival is reportedly higher in the US than in Europe. The first worldwide study (CONCORD) found wide international differences in age-standardized survival. The aim of this study is to explain these survival differences. Population-based data on stage at diagnosis, diagnostic procedures, treatment and follow-up were collected for about 20,000 women diagnosed with breast cancer aged 15-99 years during 1996-98 in 7 US states and 12 European countries. Age-standardized net survival and the excess hazard of death up to 5 years after diagnosis were estimated by jurisdiction (registry, country, European region), age and stage with flexible parametric models. Breast cancers were generally less advanced in the US than in Europe. Stage also varied less between US states than between European jurisdictions. Early, node-negative tumors were more frequent in the US (39%) than in Europe (32%), while locally advanced tumors were twice as frequent in Europe (8%), and metastatic tumors of similar frequency (5-6%). Net survival in Northern, Western and Southern Europe (81-84%) was similar to that in the US (84%), but lower in Eastern Europe (69%). For the first 3 years after diagnosis the mean excess hazard was higher in Eastern Europe than elsewhere: the difference was most marked for women aged 70-99 years, and mainly confined to women with locally advanced or metastatic tumors. Differences in breast cancer survival between Europe and the US in the late 1990s were mainly explained by lower survival in Eastern Europe, where low healthcare expenditure may have constrained the quality of treatment.
Subject(s)
Breast Neoplasms/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Europe/epidemiology , Female , Follow-Up Studies , Humans , Middle Aged , Registries , United States/epidemiology , Young AdultABSTRACT
The beneficial impact of screening mammography on breast cancer outcome continues to be debated as demonstrated by guidelines published by the United States Preventive Services Task Force. A previous report from Rhode Island, which has a very high rate of mammographic screening, demonstrated significant improvements in invasive breast cancer presentation and mortality through 2001. This report updates data through 2008 to determine whether previous favorable trends continued. Rhode Island Cancer Registry data regarding invasive breast cancer presentation and mortality in 17,522 female residents diagnosed between 1987 and 2008, inclusive, were analyzed for demographic and pathological factors. Data were analyzed by four time periods: 1987-1992, 1993-1998, 1999-2003, and 2004-2008 and overall. Statistically significant improvements occurred over the four successive time periods, in mean cancer size (23.7, 20.9, 19.6, and 19.3 mm, p < 0.0001), pathologic grade (Grade I: 12, 15, 19, and 17 %; Grade III 57, 41, 36, and 35 %, p < 0.0001), breast conserving surgery (38, 56, 67, and 71 %, p < 0.0001) and mortality (37.3, 31.4, 25.1, and 22.6 per 100,000/year, p < 0.0001). The results showed that high screening rates favorably impacted presentation of and mortality from invasive breast cancer in Rhode Island. From 1987 to 2008, there has been a 39 % decline in breast cancer mortality considering 5 year periods (37.3 vs. 22.6 deaths per 100,000) and 41 % comparing the period from 1990 to 2008, which may exceed the goal of 50 % mortality reduction by 2015 established by the American Cancer Society.
Subject(s)
Breast Neoplasms/mortality , Breast Neoplasms/pathology , Lymphatic Metastasis/pathology , Mammography/statistics & numerical data , Adult , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/surgery , Early Detection of Cancer/statistics & numerical data , Female , Humans , Mammography/methods , Mass Screening , Mastectomy, Segmental/statistics & numerical data , Middle Aged , Rhode Island/epidemiologyABSTRACT
BACKGROUND: In Rhode Island, malignant melanoma of skin causes about 30 deaths a year. Early detection has been shown to reduce mortality risk. METHODS: Dermatology volunteers and public health professionals convened 27 free skin cancer screenings at public beaches in 2015-2019 to raise skin cancer awareness and screen patients for malignancy. Participants with suspicious lesions were referred for follow-up and later telephoned to ascertain outcomes. RESULTS: Of 2354 people screened, 597 (25%) were referred. 319 of 597 (53%) were later reached by telephone. 196 of 319 (61%) who had kept appointments by the time of the telephone call reported the following diagnoses: 7 malignant melanomas, 32 keratinocyte carcinomas, and 34 actinic keratoses, yielding 3.0 as number needed to biopsy (NNB), and 18.3 as number needed to screen (NNS). CONCLUSIONS: Our results demonstrate the value of convenient skin cancer screening events, suggesting the desirability of additional interventions of this type.
Subject(s)
Melanoma , Skin Neoplasms , Biopsy , Early Detection of Cancer , Humans , Mass Screening , Melanoma/diagnosis , Melanoma/epidemiology , Rhode Island/epidemiology , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiologyABSTRACT
BACKGROUND: Despite the large number of men diagnosed with localized prostate cancer, there is as yet no consensus concerning appropriate treatment. The purpose of this study was to describe the initial treatment patterns for localized prostate cancer in a population-based sample and to determine the clinical and patient characteristics associated with initial treatment and overall survival. METHODS: The analysis included 3,300 patients from seven states, diagnosed with clinically localized prostate cancer in 1997. We examined the association of sociodemographic and clinical characteristics with four treatment options: radical prostatectomy, radiation therapy, hormone therapy, and watchful waiting. Diagnostic and treatment information was abstracted from medical records. Socioeconomic measures were derived from the 2000 Census based on the patient's residence at time of diagnosis. Vital status through December 31, 2002, was obtained from medical records and linkages to state vital statistics files and the National Death Index. Multiple logistic regression analysis and Cox proportional hazards models identified factors associated with initial treatment and overall survival, respectively. RESULTS: Patients with clinically localized prostate cancer received the following treatments: radical prostatectomy (39.7%), radiation therapy (31.4%), hormone therapy (10.3%), or watchful waiting (18.6%). After multivariable adjustment, the following variables were associated with conservative treatment (hormone therapy or watchful waiting): older age, black race, being unmarried, having public insurance, having non-screen detected cancer, having normal digital rectal exam results, PSA values above 20, low Gleason score (2-4), comorbidity, and state of residence. Among patients receiving definitive treatment (radical prostatectomy or radiation therapy), older age, being unmarried, PSA values above 10, unknown Gleason score, state of residence, as well as black race in patients under 60 years of age, were associated with receipt of radiation therapy. Overall survival was related to younger age, being married, Gleason score under 8, radical prostatectomy, and state of residence. Comorbidity was only associated with risk of death within the first three years of diagnosis. CONCLUSIONS: In the absence of clear-cut evidence favoring one treatment modality over another, it is important to understand the factors that inform treatment selection. Since state of residence was a significant predictor of both treatment as well as overall survival, true regional differences probably exist in how physicians and patients select treatment options. Factors affecting treatment choice and treatment effectiveness need to be further explored in future population-based studies.
Subject(s)
Adenocarcinoma/mortality , Adenocarcinoma/therapy , Antineoplastic Agents, Hormonal/therapeutic use , Practice Patterns, Physicians'/statistics & numerical data , Prostatectomy/statistics & numerical data , Prostatic Neoplasms/mortality , Prostatic Neoplasms/therapy , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Humans , Logistic Models , Male , Middle Aged , Neoplasm Invasiveness , Observation , Odds Ratio , Patient Selection , Proportional Hazards Models , Prostatic Neoplasms/pathology , Radiotherapy/statistics & numerical data , Registries , Residence Characteristics , Risk Assessment , Risk Factors , Socioeconomic Factors , Survival Analysis , Time Factors , Treatment Outcome , United States/epidemiologyABSTRACT
Great efforts are devoted to end the HIV epidemic as it continues to have profound public health consequences in the United States and throughout the world, and new interventions and strategies are continuously needed. The use of HIV sequence data to infer transmission networks holds much promise to direct public heath interventions where they are most needed. As these new methods are being implemented, evaluating their benefits is essential. In this paper, we recognize challenges associated with such evaluation, and make the case that overcoming these challenges is key to the use of HIV sequence data in routine public health actions to disrupt HIV transmission networks.
ABSTRACT
BACKGROUND: Mycoplasma pneumoniae continues to be a significant cause of community-acquired pneumonia (CAP). A more definitive methodology for reliable detection of M. pneumoniae is needed to identify outbreaks and to prevent potentially fatal extrapulmonary complications. METHODS: We analyzed 2 outbreaks of CAP due to M. pneumoniae. Nasopharyngeal and/or oropharyngeal swab specimens and serum samples were obtained from persons with clinically defined cases, household contacts, and asymptomatic individuals. Real-time polymerase chain reaction (PCR) for M. pneumoniae was performed on all swab specimens, and the diagnostic utility was compared with that of 2 commercially available serologic test kits. RESULTS: For cases, 21% yielded positive results with real-time PCR, whereas 81% and 54% yielded positive results with the immunoglobulin M and immunoglobulin G/immunoglobulin M serologic tests, respectively. For noncases, 1.8% yielded positive results with real-time PCR, whereas 63% and 79% yielded serologically positive results with the immunoglobulin M and immunoglobulin G/immunoglobulin M kits, respectively. The sensitivity of real-time PCR decreased as the duration between symptom onset and sample collection increased, with a peak sensitivity of 48% at 0-21 days. A specificity of 43% for the immunoglobulin M antibody detection assay was observed for persons aged 10-18 years, but the sensitivity increased to 82% for persons aged 19 years. DISCUSSION: Thorough data analysis indicated that no single available test was reliable for the identification of an outbreak of CAP due to M. pneumoniae. A combination of testing methodologies proved to be the most reliable approach for identification of outbreaks of CAP due to M. pneumoniae, especially in the absence of other suspected respiratory pathogens.
Subject(s)
Clinical Laboratory Techniques/methods , Community-Acquired Infections/diagnosis , Community-Acquired Infections/epidemiology , Disease Outbreaks , Mycoplasma pneumoniae/isolation & purification , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Mycoplasma/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Child , Child, Preschool , Community-Acquired Infections/microbiology , Humans , Infant , Infant, Newborn , Middle Aged , Pharynx/microbiology , Pneumonia, Mycoplasma/microbiology , Polymerase Chain Reaction/methods , Sensitivity and Specificity , Serum/immunology , Young AdultABSTRACT
OBJECTIVES: This study examined the impact of guideline-concordant therapy on the survival difference between non-Hispanic black (NHB) and non-Hispanic white (NHW) women with localized breast cancer. METHODS: Data analyzed were from the CDC's NPCR Patterns of Care study in which seven population-based state cancer registries participated. We randomly selected 2,362 women who were diagnosed with a first primary localized breast cancer in 1997. Data were abstracted from hospital records, supplemented by information from physician offices and by linkages with state vital records and the National Death Index database. RESULTS: NHB women were more likely than NHW women to receive breast conserving surgery without radiation therapy. In addition, the percentage of NHB women with hormone receptor-positive tumors who received hormonal therapy was lower than that of NHW women. Among those with a tumor size > 3 cm, NHB women were more likely than NHW women to receive multiagent chemotherapy. After controlling for age, the risk of dying from all causes of death was 2.35 times as high for NHB women compared to NHW women. Controlling for treatment further reduced black-white difference in survival with adjustment for sociodemographic and clinical variables. CONCLUSION: NHB women were less likely than NHW women to receive guideline-concordant radiation therapy after breast conserving therapy and hormonal therapy but were more likely to receive chemotherapy. Racial differences in treatment contribute significantly to the worse survival of NHB women compared with NHW women.
Subject(s)
Antineoplastic Agents/therapeutic use , Black or African American , Breast Neoplasms/mortality , Practice Guidelines as Topic , White People , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/epidemiology , Centers for Disease Control and Prevention, U.S. , Databases as Topic , Female , Humans , Middle Aged , Prognosis , Receptors, Estrogen , Registries , Risk Factors , Treatment Outcome , United States/epidemiologyABSTRACT
In the U.S. in 2015, the proportion of people dependent on opioids approached one percent, and opioid overdose rivaled auto accidents as the leading cause of accidental death. The literature suggests a credible link between increased opioid prescribing and increased opioid addiction. Accordingly, some have suggested that limiting the number of opioid prescriptions (and the number of doses per prescription) might be effective in reducing the number of opioid-related deaths. Toward this end, we designed and piloted an evidence-based quality-improvement project in four urgent care clinics. Results of the intervention were monitored with data from a state-sponsored prescription drug-monitoring program (PDMP) by comparing opioid prescribing before and after adoption of the guideline, and in this manner, a statistically significant (P < 0.05) decline in the rate of opioid prescribing was revealed. On average, 2.43 fewer opioid prescriptions were written, per provider, per week, in weeks five through eight after promulgation (5.21, SD =4.37) than in the eight weeks before promulgation (7.64, SD =7.73). Our results suggest that implementing a simple opioid-prescribing guideline, with monitoring, can reduce sub-optimal opioid prescribing, and therefore the volume of opioids available in the community for diversion, abuse, and addiction.
Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Drug Overdose/mortality , Drug Prescriptions/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Analgesics, Opioid/poisoning , Humans , Opioid-Related Disorders/epidemiology , Practice Guidelines as Topic , Practice Patterns, Physicians'/standards , Quality Improvement/organization & administration , Rhode Island/epidemiology , RiskSubject(s)
Airports , Lung Neoplasms/epidemiology , Residence Characteristics/statistics & numerical data , Age Factors , Air Pollutants/toxicity , Behavioral Risk Factor Surveillance System , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Environmental Exposure/adverse effects , Humans , Income/statistics & numerical data , Lung Neoplasms/etiology , Respiratory Tract Diseases/epidemiology , Respiratory Tract Diseases/etiology , Rhode Island , Risk Factors , Smoking/epidemiologySubject(s)
Urinary Bladder Neoplasms/epidemiology , Urinary Bladder Neoplasms/etiology , Aged , Aged, 80 and over , Environmental Exposure/adverse effects , Female , Humans , Incidence , Male , Middle Aged , Rhode Island/epidemiology , Risk Factors , SEER Program , Smoking/adverse effects , Smoking/epidemiology , United States/epidemiologyABSTRACT
OBJECTIVE: The purpose of this study was to compare prostate cancer incidence and mortality trends between the United States and Canada over a period of approximately 30 years. METHODS: Prostate cancer incident cases were chosen from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program to estimate rates for the United States white males and from the Canadian Cancer Registry for Canadian men. National vital statistics data were used for prostate cancer mortality rates for both countries, and age-adjusted and age-specific incidence and mortality rates were calculated. Joinpoint analysis was used to identify significant changes in trends over time. RESULTS: Canada and the U.S. experienced 3.0% and 2.5% growth in age-adjusted incidence from 1969-90 and 1973-85, respectively. U.S. rates accelerated in the mid- to late 1980s. Similar patterns occurred in Canada with a one-year lag. Annual age-adjusted mortality rates in Canada were increasing 1.4% per year from 1977-93 then fell 2.7% per year from 1993-99. In the U.S., annual age-adjusted mortality rates for white males increased 0.7% from 1969-1987 and 3.0% from 1987-91, then decreased 1.2% and 4.5% during the 1991-94 and 1994-99 periods, respectively. CONCLUSIONS: Recent incidence patterns observed between the U.S. and Canada suggest a strong relationship to prostate-specific antigen (PSA) test use. Clinical trials are required to determine any effects of PSA test use on prostate cancer and overall mortality.
Subject(s)
Prostatic Neoplasms/epidemiology , SEER Program , Age Factors , Aged , Aged, 80 and over , Canada/epidemiology , Cohort Studies , Confidence Intervals , Data Interpretation, Statistical , Humans , Male , Middle Aged , Prostate-Specific Antigen/blood , Prostatic Neoplasms/mortality , Racial Groups , United States/epidemiologyABSTRACT
Thanks largely to systematic larviciding by the State's 39 municipalities, and aided by the public's destruction of "backyard" mosquito habitats and adoption of personal protective measures (clothing, repellant), Rhode Island minimized the potential human burden of WNV during the 2003 mosquito season (six serious WNV cases, one death, and no reports of WNV-tainted blood donations). The potential burden of WNV on domestic animals was also reduced through immunization. Nonetheless, the State's first WNV death reminds us of the danger this disease poses for the very young, for elders, and for people of all ages who are immune-compromised. Similarly, the widespread location of birds positive for WNV signifies the ubiquity of risk. All mosquitoes must be avoided. Based on its experience with WNV control over the past few years, the State will continue and enhance its surveillance and control efforts in 2004. Once again, systematic larviciding by municipalities and continuing public education through multiple channels will form the backbone of control, supported by active surveillance for the virus in the wild, in domestic animals, and in humans. For the latter effort, the vigilance of the health care community is of signal importance to the protection of the public. Every human case is investigated thoroughly, to establish as accurately as possible the time and place of exposure. DEM and HEALTH use this information to assess potential weaknesses in WNV control efforts, and to take corrective action, as necessary. Health care providers also play an essential role in public education, reminding patients (all patients, but especially the very young, elders, and the immune-compromised) to avoid mosquito bites. Discussing the avoidance of mosquito bites with patients who engage in regular outdoor activity is especially important. School physicians and the medical directors of nursing homes are well-positioned to keep mosquito control and avoidance on the agenda of their respective institutions. Together, we can control the burden of this disease among domestic animals and humans, if we continue to pursue mosquito control and personal protection aggressively. If we don't, the potential for tragedy is tremendous, as evidenced by the recent experience of other regions of the country.
Subject(s)
Culicidae , Public Health Administration , West Nile Fever/epidemiology , West Nile Fever/prevention & control , Animals , Disease Notification , Health Education , Health Promotion , Humans , Insect Control/methods , Insect Repellents , Insect Vectors , Local Government , Population Surveillance , Program Evaluation , Rhode Island/epidemiology , United States/epidemiology , West Nile Fever/transmissionSubject(s)
Lyme Disease/epidemiology , Humans , Incidence , Rhode Island/epidemiology , United States/epidemiologyABSTRACT
Metachronous cancer (multiple primary tumors developing at intervals) will appear more commonly as cancer patients live longer lives. In this report, we use data from the Rhode Island Cancer Registry to look at commonly occurring metachronous cancers, their frequency over time, and the implications for cancer survivorship. Sequence two (refers to the chronologically second primary tumor diagnosed for a given patient) and higher primary malignant neoplasms were identified in cancer case reports made to the Rhode Island Cancer Registry, 1987-2009, and used to construct annual, age-adjusted, sequence-specific incidence rates for all cancers combined, and age-adjusted, site-specific incidence rates for common second and higher-order primary malignant neoplasms over the entire observational period. During the period of observation, the proportion of all cancers diagnosed as sequence two and higher primary tumors among males increased steadily from 11.5 to 20.3 percent, while the proportion of all cancers diagnosed as sequence two and higher primary tumors among females increased from 12.8 to 20.7 percent. A mere four cancer types--lung (and bronchus), colon (and rectum), breast, and prostate--account for over half of all sequence two and higher cancer diagnoses (54.3 percent). The average interval between first cancers and second cancers is 6.5 years for men and 4.8 years for women. Such is the "career" of a cancer survivor today that he or she has about a one in four chance of developing a second cancer. This statistic suggests the need for strong and lasting social support networks. Furthermore, the average interval between first and second cancers is substantial, and suggests opportunities for interventions (prevention and screening) that might reduce the burden of sequence two and higher cancers.
Subject(s)
Neoplasms, Second Primary , Female , Humans , Male , Neoplasms, Second Primary/epidemiologyABSTRACT
OBJECTIVE: To learn the frequency of conflicting race/ethnicity reports, to examine patterns of conflicting reports, and to identify possible avenues for data quality improvement. METHODS: As part of the Data Improvement Project on Patient Ethnicity and Race (DIPPER), an analysis of conflicting race/ethnicity reports for cancer cases was conducted. Using matched hospital discharge data and central cancer registry data from 2009, the race/ethnicity of patients in the 2 datasets were compared. Those with conflicting reports ("mismatched") were examined more closely. From a sample of 2,356 patients, 187 had conflicting reports for their race (7.9%) and 357 had conflicting reports for their ethnicity (15% was thus developed). RESULTS: In the 2009 hospital discharge data, an unknown response occurred nearly twice as often for Hispanic ethnicity as for race. Almost 85% of the mismatched race cases were classified as non-white in the hospital discharge data and white in the central cancer registry data. The most common ethnicity mismatch was coded unknown by the hospital but non-Hispanic by the registry. CONCLUSIONS: Hospital cancer registrars occasionally lack easy access to race and, more often, ethnicity data. More attention should be given to discrepancies (including allowing staff to flag and verify existing data), and staff training should improve both perceived and real data accuracy. In the future, hospitals and registries would be better served by pairing race and ethnicity together in the electronic medical record. This would ensure quick, easy access for cancer registrars. Perhaps standard setters should add ethnicity to the gold standard criteria for registries.
Subject(s)
Bias , Ethnicity/classification , Neoplasms/ethnology , Quality Improvement , Racial Groups/classification , Data Collection , Humans , Patient Discharge/statistics & numerical data , Registries/standards , Rhode IslandABSTRACT
OBJECTIVES: To assess the extent to which stage at diagnosis and adherence to treatment guidelines may explain the persistent differences in colorectal cancer survival between the USA and Europe. DESIGN: A high-resolution study using detailed clinical data on Dukes' stage, diagnostic procedures, treatment and follow-up, collected directly from medical records by trained abstractors under a single protocol, with standardised quality control and central statistical analysis. SETTING AND PARTICIPANTS: 21 population-based registries in seven US states and nine European countries provided data for random samples comprising 12 523 adults (15-99 years) diagnosed with colorectal cancer during 1996-1998. OUTCOME MEASURES: Logistic regression models were used to compare adherence to 'standard care' in the USA and Europe. Net survival and excess risk of death were estimated with flexible parametric models. RESULTS: The proportion of Dukes' A and B tumours was similar in the USA and Europe, while that of Dukes' C was more frequent in the USA (38% vs 21%) and of Dukes' D more frequent in Europe (22% vs 10%). Resection with curative intent was more frequent in the USA (85% vs 75%). Elderly patients (75-99 years) were 70-90% less likely to receive radiotherapy and chemotherapy. Age-standardised 5-year net survival was similar in the USA (58%) and Northern and Western Europe (54-56%) and lowest in Eastern Europe (42%). The mean excess hazard up to 5 years after diagnosis was highest in Eastern Europe, especially among elderly patients and those with Dukes' D tumours. CONCLUSIONS: The wide differences in colorectal cancer survival between Europe and the USA in the late 1990s are probably attributable to earlier stage and more extensive use of surgery and adjuvant treatment in the USA. Elderly patients with colorectal cancer received surgery, chemotherapy or radiotherapy less often than younger patients, despite evidence that they could also have benefited.